IDELVION(R) (rFIX-FP) - CHMP recommendation
Filed with ASX · · 2 pages · English
® ® ® IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B. IDELVION is CSL Behring’s long-acting fusion protein, linking recombinant coagulation factor IX ® with recombinant albumin. IDELVION was designated as an orphan medicinal product in 2010 by the European Commission. ® “CHMP’s positive opinion for IDELVION moves us one step closer to bringing this long- acting treatment
Earlier from CSL
- Half Year Accounts
- Announcement of buy-back - Appendix 3C
- US FDA Accepts for Review rFVIII BLA
- Update on Novartis Influenza Vaccine Acquisition
- Response to an ASX Query
Later from CSL
- IDELVION(R) (rFIX-FP) - FDA approval
- Changes relating to buy-back - Appendix 3D
- Appendix 4E, FY Results and Analysts Presentation
- Half Yearly Report and Accounts
- CSL Settles US Class Action and Updated Profit Guidance
Follow CSL into a list and get an email when it puts out news.
Follow CSL